Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Aug;19(8):468-469.
doi: 10.1038/s41584-023-00991-9.

A leading role for interferon as a treatment target in Sjögren syndrome

Gwenny M Verstappen  1 , Frans G M Kroese  2
Affiliations
Comment

A leading role for interferon as a treatment target in Sjögren syndrome

Gwenny M Verstappen et al. Nat Rev Rheumatol. 2023 Aug.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Bodewes, I. L. A., Björk, A., Versnel, M. A. & Wahren-Herlenius, M. Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome. Rheumatology (Oxford) 60, 2561–2573 (2019). - DOI
    1. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014). - DOI - PubMed - PMC
    1. Felten, R. et al. Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach. Rheumatology (Oxford) https://doi.org/10.1093/rheumatology/kead096 (2023). - DOI - PubMed
    1. Verstappen, G. M., Pringle, S., Bootsma, H. & Kroese, F. G. M. Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat. Rev. Rheumatol. 17, 333–348 (2021). - DOI - PubMed - PMC
    1. Juarez, M. et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome. Rheumatology (Oxford) 60, 1364–1375 (2021). - DOI - PubMed

Publication types

LinkOut - more resources